Sourcing Quality

Not all Ashwagandha products contain meaningful WFA exposure. For oncology use, the sourcing question is not cosmetic. It determines whether the product even matches the biology being discussed.

What makes a product coherent?

1. Plant part must be explicit

Leaf extract is the relevant starting material for WFA-standardised oncology products. Root extract is the usual base for adaptogenic Ashwagandha products and typically contains much less WFA.

A root extract standardised to total withanolides is not the same as a leaf-derived WFA-standardised product.

2. WFA standardisation must be explicit

The label should state WFA content, not just total withanolides.

This distinction is critical. Total withanolide percentages can look impressive while actual WFA content remains modest.

3. Delivery system must be defined

Given WFA's poor standard oral bioavailability, a product without a delivery system is hard to take seriously for oncology use.

Look for a named formulation approach such as:

• liposomal

• pro-liposomal

• chitosan-phospholipid liposomal

For more context, see Liposomal Encapsulation of Anti-cancer Compounds.

4. Third-party testing must be available

A credible product should be able to show batch-level confirmation of:

• actual WFA content by HPLC

• heavy metal testing

• pesticide screening

• microbiological safety

5. Dose transparency matters

The product should clearly state WFA exposure per capsule or serving. If the label forces readers to infer it indirectly, that is a quality warning.

The biggest buying mistake

The most common mistake is buying a standard adaptogenic root extract such as KSM-66 or Sensoril and expecting oncology-relevant WFA activity.

Those products are built for stress, sleep, and broader adaptogenic use. They are not interchangeable with high-WFA, oncology-oriented formulations.

A second common mistake is buying a leaf extract without a defined delivery system. High nominal WFA content in a powder does not guarantee useful plasma exposure.

Withaferin A Quality markers

Bottom line

If the product does not name the plant part, does not state WFA content, and does not explain the delivery system, it should not be assumed to match the evidence base for WFA in oncology.

See W section in our Trusted Suppliers and Discounts page
for the only WFA product available worldwide that meets all the criteria.

IMPORTANT: Please do not assume that any “ashwagandha” supplement will provide oncology‑relevant WFA exposure. This page was created to highlight Withaferin A‑focused targets, and specialised WFA‑standardised leaf extracts are required, not general ashwagandha root products. For support in sourcing see the Sourcing Quality page within this WFA in Oncology Hub.

Key references

(Leaf vs root WFA content.)
Source: Kulkarni S. K. et al., “Comparative study of Withaferin A and Withanolide A in different Withania somnifera plant parts,” SSRN preprint.
https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID3530709_code3969441.pdf

(Whole-plant extract profiling and withanolide composition.)
Source: Kurapati K. R. V. et al., “Chemical, microbial and safety profiling of a standardized Withania somnifera extract,” Functional Foods in Health and Disease.
https://www.ffhdj.com/index.php/ffhd/article/download/1071/1779

(Improved bioavailability with liposomal WFA.)
Source: Yadav K. S. et al., “Improving Oral Bioavailability and Pharmacokinetics of Liposomal Withaferin A,” International Journal of Pharmaceutics.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3666019/

Access and availability:
Source: MCS Formulas, “Withaferin A Pro Liposomal.”
50 mg WFA per capsule. Available via healthcare professional request.
https://www.mcsformulas.com/vitamins-supplements/withaferin-a-pro-liposomal/ref/14